No Survival Benefit Found When Radium-223 is Added to Abiraterone in mCRPC
October 20th 2018According to a presentation from the ERA 223 trial atthe 2018 ESMO Congress, no improvements in survival endpoints were seen with the addition of radium-223 dichloride to abiraterone acetate and prednisone in patients with metastatic castration-resistant prostate cancer.
Read More
Frontline Atezolizumab and Nab-Paclitaxel Demonstrate PFS Benefit in PD-L1+ mTNBC
October 20th 2018The combination of atezolizumab and nab-paclitaxel demonstrated a 2.5-month benefit in progression-free survival over nab-paclitaxel alone in patients with PD-L1–positive metastatic triple-negative breast cancer, according to findings of the phase III IMpassion130 trial presented at the 2018 ESMO Congress.
Read More
Presence of MET, EGFR C797S Mutations Linked With Osimertinib Resistance in NSCLC
October 20th 2018Patients with <em>EGFR</em>-mutant non–small cell lung cancer who had <em>MET</em> amplification and <em>EGFR</em> C797S mutations were most likely to have resistance to first-line treatment with osimertinib (Tagrisso), according to preliminary findings presented at the 2018 ESMO Congress.
Read More
Three-Drug Regimen Active in BRAF-Mutant Melanoma
September 22nd 2017Triplet therapy for advanced, <em>BRAF</em> V600-mutant melanoma led to objective responses in 73% of a small group of patients enrolled in a phase I trial, according to updated results reported at the 2017 ESMO Annual Congress in Madrid.
Read More
Dr. West Discusses Results of the Phase III FLAURA Study in NSCLC
September 20th 2017H. Jack West, MD, medical oncologist, Swedish Cancer Institute of Swedish Medical Center, discusses the results of the phase III FLAURA study of frontline osimertinib (Tagrisso) in patients with EGFR-mutant non–small cell lung cancer (NSCLC).
Read More
Study Identifies Subset of NSCLC Patients Who Experience Hyperprogression After Immunotherapy
September 19th 2017A multicenter retrospective analysis presented at the 2017 ESMO Congress found that a newly defined subset of patients treated with anti-PD-1/PD-L1 immunotherapy experienced accelerated tumor growth indicative of hyperprogressive disease (HPD).
Read More
Vx-001, a cancer vaccine that employs a new strategy targeting a universal tumor antigen, significantly improved overall survival in patients with advanced or metastatic non–small cell lung cancer who developed an immune response to the vaccine, according to findings presented at the 2017 ESMO Annual Congress in Madrid, Spain.
Read More
Enhanced Surveillance Post-Surgery Not Associated With Longer Survival in NSCLC
September 12th 2017There was no overall survival improvement seen by expanding surveillance from chest x-ray to follow-up with PET-CT scan after surgery for patients with early-stage non–small cell lung cancer, according to data reported during the 2017 ESMO Congress.
Read More
Nab-Paclitaxel Demonstrates Efficacy Alone and With Durvalumab in NSCLC
September 12th 2017According to findings presented at the 2017 ESMO Congress, nab-paclitaxel monotherapy demonstrated efficacy in patients with pretreated advanced nonsquamous non–small cell lung cancer that is not improved by the addition of CC-486.
Read More
Continuous Nivolumab Treatment Leads to Improved PFS in Pretreated NSCLC
September 12th 2017In patients with previously treated advanced non-small cell lung cancer, <sup> </sup>superior progression-free survival was induced with continuous treatment with nivolumab until disease progression compared with a 1-year fixed duration treatment.
Read More
Mature OS Results Favor Pembrolizumab Versus Chemotherapy for Patients With Advanced Bladder Cancer
September 12th 2017Median overall survival findings from treatment with pembrolizumab (Keytruda) were significantly longer compared with chemotherapy in patients with recurrent, advanced urothelial carcinoma, according to mature results from the phase III KEYNOTE-045 study.
Read More
Significance of the Phase III FLAURA Study in EGFR+ NSCLC
September 11th 2017Joshua Bauml, MD, assistant professor, Perelman School of Medicine, University of Pennsylvania, discusses the randomized phase III FLAURA study of frontline osimertinib (Tagrisso) in patients with EGFR-mutant non-small cell lung cancer.
Read More
Abemaciclib Added to Aromatase Inhibitors Allows for PFS Boost in HR+/HER2- Breast Cancer
September 11th 2017When abemaciclib was added to a non-steroidal aromatase inhibitor in treatment-naive patients with HER2-negative, HR-positive advanced breast cancer, the combination reduced the risk of progression of disease or death by 46% compared with either anastrozole or letrozole alone, according to findings from the phase III MONARCH 3 trial.
Read More
An Update on Avelumab as Monotherapy for Urothelial Carcinoma
September 11th 2017Andrea Apolo, MD, medical oncologist at the National Cancer Institute and chief of the bladder cancer section of the Genitourinary Malignancies Branch, discusses the recent updates presented at the 2017 ESMO Annual Congress regarding avelumab (Bavencio) monotherapy for patients with urothelial carcinoma.
Read More
Atezolizumab/Bevacizumab Combo Leads to Improved PFS in Kidney Cancer
September 11th 2017The combination of atezolizumab (Tecentriq) and bevacizumab (Avastin) demonstrated greater progression-free survival in patients with untreated metatatic renal cell carcinoma compared with standard sunitinib (Sutent), according to findings presented at the 2017 ESMO Congress held in Madrid, Spain.
Read More
Avelumab Treatment in Patients With Metastatic Merkel Cell Carcinoma
September 10th 2017Celeste Lebbé, MD, from the Hôpital Saint Louis, in Paris, France, discusses avelumab treatment in chemotherapy-naive patients with distant metastatic Merkel cell carcinoma during the 2017 ESMO Annual Congress.
Read More
Epacadostat/Pembrolizumab Combo Demonstrates Promising Activity in Advanced Melanoma
September 10th 2017In findings reported at the 2017 ESMO Annual congress in Madrid, a majority of patients with advanced melanoma responded to the combination of pembrolizumab (Keytruda) and the investigational IDO1 inhibitor epacadostat.
Read More
Priming Immune System Before Nivolumab Improves Response in Metastatic TNBC
September 10th 2017In patients with metastatic triple negative breast cancer, turning a nonimmunogenic (“cold”) tumor into an immunogenic (“hot”) tumor appears to be feasible, thereby improving sensitivity to immune therapy with nivolumab.
Read More
PFS Benefit in NSCLC Immunotherapy Predicted With Liquid Biopsy for Mutation Burden
September 10th 2017According to a retrospective analysis of a randomized study presented at the 2017 ESMO Congress, a liquid biopsy that measures tumor mutational burden showed promise for predicting benefit in patients with non–small cell lung cancer treated with a checkpoint inhibitor.
Read More
Binimetinib/Encorafenib Combo Superior to Single-Agent Therapy in BRAF+ Melanoma
September 9th 2017For patients with <em>BRAF</em>-mutant advanced melanoma, the BRAF inhibitor encorafenib combined with the MEK inhibitor binimetinib demonstrated significant improvements in progression-free survival (PFS) compared with single-agent vemurafenib or encorafenib, according to updated findings from the phase III COLUMBUS trial presented at the 2017 ESMO Congress.
Read More
Durvalumab a Promising Option for Patients With Locally Advanced Lung Cancer
September 9th 2017Treatment with the PD-L1 inhibitor durvalumab (Imfinzi) improved median PFS by 11.2 months compared with placebo for patients with locally advanced, unresectable stage III non–small cell lung cancer who had not progressed following chemoradiotherapy, according to phase III results from the PACIFIC trial presented at the 2017 ESMO Congress.
Read More
Results of Phase III FLAURA Study Show Benefit of Frontline Osimertinib in EGFR+ NSCLC
September 9th 2017In results from the phase III FLAURA study of frontline osimertinib (Tagrisso) in patients with <em>EGFR</em>-mutant non–small cell lung cancer, osimertinib demonstrated a progression-free survival rate of 18.9 months (95% CI, 12.5-21.4), which was significantly improved over standard therapy.
Read More
Dr. Luke Discusses the Combination of Epacadostat and Pembrolizumab in Melanoma
September 9th 2017Jason J. Luke, MD, assistant professor of Medicine, The University of Chicago Medicine, discusses the combination of epacadostat and pembrolizumab (Keytruda) for the treatment of melanoma during the 2017 ESMO Annual Congress.
Read More
Alectinib Demonstrates Promising Efficacy for ALK+ NSCLC With CNS Brain Metastases
September 9th 2017According to findings from the phase III ALUR and ALEX studies announced ahead of the 2017 ESMO Congress,<sup> </sup>Alectinib demonstrated promising efficacy for patients with <em>ALK</em>-translocated non–small cell lung cancer with central nervous system metastases in both the first- and second-line setting.
Read More
Taselisib/Letrozole Combo Active in ER+/HER2- Early Breast Cancer
September 8th 2017The combination of taselisib and standard letrozole improved the objective response rate compared to letrozole with a placebo in postmenopausal women with estrogen receptor-positive and HER2-negative early breast cancer, according to findings from the LORELEI study presented at the 2017 ESMO Congress in Madrid, Spain.
Read More
Rucaparib Highly Effective as Maintenance Therapy in Ovarian Cancer Subtypes
September 8th 2017The PARP inhibitor Rucaparib (Rubraca) improved median progression-free survival by 11.2 months compared with placebo as a maintenance treatment for patients with <em>BRCA</em>-mutant platinum-sensitive ovarian cancer, according to findings from the phase III ARIEL3 trial presented at the 2017 ESMO Congress.
Read More
Toxicities Associated With Rucaparib for the Treatment of Ovarian Cancer
September 8th 2017Jonathan Ledermann, MD, professor of medical oncology in the University College London Cancer Institute and director of Cancer Research UK and UCL Cancer Trials Centre, discusses the toxicities associated with rucaparib (Rubraca) for the treatment of ovarian cancer.
Read More
Late-Breaking Abstracts at ESMO Could Potentially Change Lung Cancer Practice
September 7th 2017The 2017 ESMO Annual Congress, taking place September 8 to 12 in Madrid, Spain, will feature several late-breaking abstracts that are poised to change the future of treatment for patients with lung cancer, pending their results, including the phase III PACIFIC and FLAURA studies.
Read More
Epacadostat/Pembrolizumab a Promising, Timely Combo for Melanoma, Expert Says
September 7th 2017Omid Hamid, MD, shares the top melanoma abstracts to look out for at the 2017 ESMO Annual Congress, which is taking place September 8 to 12 in Madrid, Spain, as well as some background on the promising phase I/II results he will be presenting for the combination of epacadostat plus pembrolizumab in patients with advanced melanoma.
Read More